Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-6036 in KRAS G12C-mutated advanced or metastatic solid tumors
NL-OMON59023Phase 1Active, not recruiting
- Sponsor
- Genentech
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of divarasib in Nonhematologic neoplasms (2 arms), sponsored by Genentech. Started Sep 2021; status: active, not recruiting.
02
Drugs
divarasib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON59023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59023.